<DOC>
	<DOCNO>NCT00354302</DOCNO>
	<brief_summary>RATIONALE : Learning effect exemestane anastrozole bone mineral density postmenopausal woman primary breast cancer may help plan treatment , decrease risk break bone , help patient live comfortably . PURPOSE : This phase III trial study bone mineral density postmenopausal woman primary breast cancer receive treatment clinical trial CAN-NCIC-MA27 .</brief_summary>
	<brief_title>Bone Mineral Density Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment Clinical Trial CAN-NCIC-MA27</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether clinically relevant difference bone mineral density ( BMD ) 2 year postmenopausal woman primary breast cancer ( without osteopenia osteoporosis ) treat exemestane vs anastrozole protocol CAN-NCIC-MA27 . OUTLINE : This multicenter , companion study . Patients stratify accord baseline bone mineral density ( BMD ) measurement ( T-score* ≥ -2.0 standard deviation [ SD ] [ osteopenia osteoporosis ] vs T-score* &lt; -2.0 SD ) . NOTE : *The low two T-scores : L1-L4 total hip Blood sample identification bone biomarkers ( formation marker : serum amino-terminal procollagen 1 extension peptide [ P1NP ] resorption marker : serum N-telopeptide ) obtain baseline 6 12 month . BMD determine dual-energy x-ray absorptiometry ( DEXA ) baseline annually 5 year ( long patient receive treatment protocol CAN-NCIC-MA27 ) . Patients receive oral calcium oral cholecalciferol ( vitamin D ) daily . Patients osteopenia osteoporosis ( stratum II ) also receive oral bisphosphonate therapy PROJECTED ACCRUAL : A total 408 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Enrolled meet eligibility requirement protocol CANNCICMA27 Acceptable quality dualenergy xray absorptiometry ( DEXA ) L1L4 posteroanterior spine hip within 12 week prior randomization protocol CANNCICMA27 Hormone receptor status : Estrogen receptor and/or progesterone receptorpositive tumor PATIENT CHARACTERISTICS : Female Postmenopausal No malabsorption syndrome No know cholecalciferol ( vitamin D ) deficiency , active hyper hypoparathyroidism , Paget 's disease No uncontrolled thyroid disease , Cushing 's disease , pituitary disease No bone disease ( include osteomalacia osteogenesis imperfecta ) PRIOR CONCURRENT THERAPY : More 6 month since prior drug ( investigational ) , include bisphosphonates , prevention osteoporosis ( stratum I ) More 12 month since prior concurrent anticonvulsant More 6 month since prior concurrent corticosteroid dose &gt; 5 mg/day prednisone ( equivalent ) &gt; 2 week More 12 month since prior concurrent anabolic steroids No prior bisphosphonates ( stratum II ) No concurrent sodium fluoride daily dos ≥ 5 mg/day No longterm ( i.e. , &gt; 6 month ) use coumarins No concurrent drug ( investigational ) , include bisphosphonates , prevention osteoporosis ( patient osteopenia osteoporosis [ stratum I ] )</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>